Transfusion in autoimmune hemolytic anemia: comparison of two different strategies
Article Sidebar
Main Article Content
Abstract
Objective: Autoimmune Hemolytic Anaemia (AIHA) is a condition in which red blood cells (RBC) are destroyed by autoantibodies. Clinicians tend to avoid the transfusion in AIHA patients who has difficulties during pre-transfusional testing. Depending on the institutional policy, the transfusion of the selected least incompatible RBC unit is a strategy. Since ORh(-) RBCs are the universal RBC donor type, the transfusion of the group ORh(-) RBC is selected in AIHA patients. In this study, we compared the effects of group ORh(-) RBC or least match incompatible same type of blood product transfusion in AIHA patients.
Material and Methods: The study included newly-diagnosed AIHA patients without active bleeding who required transfusion due to symptomatic anemia. ORh(-) RBC was transfused to the patients who had different blood groups and for the other patients, the least match incompatible same type blood product was transfused. Pre- and post-transfusion hematological and biochemical indicators were reported and compared.
Results: We determined that; there was no significant difference between groups regarding the increase in Hb levels and hemolysis parameters. In correlation analysis, the lower the pre-transfusion MCV value, the higher the LDH change. The lower the pre-transfusion MCV value, the decrease in hemolysis was higher.
Conclusion: Clinicians should not avoid transfusion for critically anemic AIHA patients for whom compatible RBC has not been found. Both group ORh(-) types of RBCs and same type least incompatible RBCs can be preferred for transfusion in critically patients when further compatibility testing procedures for alloantibodies detection cannot be performed.
Downloads
Article Details
Accepted 2020-08-12
Published 2020-08-27
References
Petz LD. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol. 2004;124:712-6.
Carson JL, Grossman BJ, Kleinman S, Tinmout AT, Marques MB, Fung MK, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med. 2012;157:49-58.
Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol. 1988;10:257-64.
Laine ML, Beattie KM. Frequency of alloantibodies accompanying autoantibodies. Transfusion. 1985;25:545-6
Ziman A, Cohn C, Carey PM, Dunbar NM, Fung MK, Greinacher A et al. Warm-reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice. Transfusion. 2017;57:463-77.
Dutton RP, Shih D, Edelman BB, Hess J, Scalea TM. Safety of uncrossmatched type-O red cells for resuscitation from hemorrhagic shock. J Trauma. 2005;59:1445-9.
Maley M, Bruce DG, Babb RG, Wells AW, Williams M. The incidence of red cell alloantibodies underlying panreactive warm autoantibodies. Immunohematology. 2005;21:122-5.
Das SS, Zaman RU, Safi M. Incompatible blood transfusion: Challenging yet lifesaving in the management of acute severe autoimmune hemolytic anemia. Asian J Transfus Sci. 2014;8:105-8.
Park SH, Choe WH, Kwon SW. Red Blood Cell Transfusion in Patients With Autoantibodies: Is It Effective and Safe Without Increasing Hemolysis Risk?. Ann Lab Med. 2015;35:436-44.
Chen C, Wang L, Han B, Qin L, Ying B. Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions. Medicine (Baltimore). 2020;99:e18739.
Milkins C, Berryman J, Cantwell C, Haggas R, Jones J, Rowley M et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfus Med. 2013;23:3-35.